William E Whitehead

List of Publications by Citations

133 papers	16,281 citations	60 h-index	127 g-index
142 ext. papers	18,759 ext. citations	5.2 avg, IF	6.41 L-index

#	Paper	IF	Citations
133	U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Digestive Diseases and Sciences*, **1993**, 38, 1569-80	4	1727
132	Prevalence of symptomatic pelvic floor disorders in US women. *JAMA - Journal of the American Medical Association*, **2008**, 300, 1311-6	27.4	1125
131	AGA technical review on irritable bowel syndrome. *Gastroenterology*, **2002**, 123, 2108-31	13.3	1071
130	Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?. *Gastroenterology*, **2002**, 122, 1140-56	13.3	804
129	Tolerance for rectosigmoid distention in irritable bowel syndrome. *Gastroenterology*, **1990**, 98, 1187-92	13.3	531
128	Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. *Gastroenterology*, **2003**, 125, 19-31	13.3	477
127	Irritable bowel syndrome: a technical review for practice guideline development. *Gastroenterology*, **1997**, 112, 2120-37	13.3	459
126	Fecal incontinence in US adults: epidemiology and risk factors. *Gastroenterology*, **2009**, 137, 512-7, 517.e1-2	13.3	436
125	Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. *Gastroenterology*, **1988**, 95, 709-14	13.3	423
124	Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. *Digestive Diseases and Sciences*, **1980**, 25, 404-13	4	404
123	AGA technical review on anorectal testing techniques. *Gastroenterology*, **1999**, 116, 735-60	13.3	366
122	Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. *Gastroenterology*, **2006**, 130, 657-64	13.3	313
121	Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. *Digestive Diseases and Sciences*, **1997**, 42, 223-41	4	301
120	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. *Gastroenterology*, **2021**, 160, 99-114.e3	13.3	285
119	Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. *American Journal of Gastroenterology*, **2000**, 95, 999-1007	0.7	276
118	Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception. *Gastroenterology*, **1998**, 115, 1263-71	13.3	256
117	Biofeedback benefits only patients with outlet dysfunction, not patients with isolated slow transit constipation. *Gastroenterology*, **2005**, 129, 86-97	13.3	254

116	Design of treatment trials for functional gastrointestinal disorders. *Gastroenterology*, **2006**, 130, 1538-51	13.3	252
115	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. *Gut*, **2017**, 66, 1075-1082	19.2	242
114	Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. *Gastroenterology*, **2016**,	13.3	242
113	Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. *Diseases of the Colon and Rectum*, **2007**, 50, 428-41	3.1	211
112	ACG clinical guideline: management of benign anorectal disorders. *American Journal of Gastroenterology*, **2014**, 109, 1141-57; (Quiz) 1058	0.7	201
111	Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. *American Journal of Gastroenterology*, **2011**, 106, 1678-88	0.7	179
110	Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence. *Diseases of the Colon and Rectum*, **2009**, 52, 1730-7	3.1	178
109	Epidemiology, pathophysiology, and classification of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) workshop. *American Journal of Gastroenterology*, **2015**, 110, 127-36	0.7	173
108	Treatment options for fecal incontinence. *Diseases of the Colon and Rectum*, **2001**, 44, 131-42; discussion 142-4	3.1	169
107	Anorectal functional testing: review of collective experience. *American Journal of Gastroenterology*, **2002**, 97, 232-40	0.7	168
106	Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. *Alimentary Pharmacology and Therapeutics*, **2007**, 26, 237-48	6.1	153
105	Comorbidity in irritable bowel syndrome. *American Journal of Gastroenterology*, **2007**, 102, 2767-76	0.7	150
104	Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. *American Journal of Gastroenterology*, **2010**, 105, 2228-34	0.7	141
103	Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. *Gut*, **2007**, 56, 1202-9	19.2	131
102	Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. *Digestive Diseases and Sciences*, **2002**, 47, 2605-14	4	130
101	Biofeedback treatment of fecal incontinence: a critical review. *Diseases of the Colon and Rectum*, **2001**, 44, 728-36	3.1	129
100	Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. *Digestive Diseases and Sciences*, **1995**, 40, 2647-55	4	126
99	Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. *American Journal of Gastroenterology*, **2008**, 103, 2550-61	0.7	121

98	Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. *Gastroenterology*, **1990**, 98, 336-40	13.3	119
97	Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. *Current Gastroenterology Reports*, **2017**, 19, 15	5	116
96	Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. *American Journal of Gastroenterology*, **2013**, 108, 796-803	0.7	115
95	Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 252-262	18.8	112
94	Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. *Gastroenterology*, **2020**, 158, 1262-1273.e3	13.3	112
93	Sensory retraining is key to biofeedback therapy for formed stool fecal incontinence. *American Journal of Gastroenterology*, **2002**, 97, 109-17	0.7	108
92	Biofeedback treatment of constipation: a critical review. *Diseases of the Colon and Rectum*, **2003**, 46, 1208-17	3.1	104
91	Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. *BMC Complementary and Alternative Medicine*, **2008**, 8, 46	4.7	97
90	Functional disorders of the anus and rectum. *Gut*, **1999**, 45 Suppl 2, II55-9	19.2	94
89	Validation of the balloon evacuation test: reproducibility and agreement with findings from anorectal manometry and electromyography. *Clinical Gastroenterology and Hepatology*, **2014**, 12, 2049-54	6.9	92
88	Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 208-16; quiz e22-3	6.9	81
87	Fecal incontinence in primary care: prevalence, diagnosis, and health care utilization. *American Journal of Obstetrics and Gynecology*, **2010**, 202, 493.e1-6	6.4	81
86	Pain from rectal distension in women with irritable bowel syndrome: relationship to sexual abuse. *Digestive Diseases and Sciences*, **1997**, 42, 796-804	4	81
85	The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. *American Journal of Gastroenterology*, **2018**, 113, 86-96	0.7	80
84	Utility of red flag symptom exclusions in the diagnosis of irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2006**, 24, 137-46	6.1	78
83	Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. *American Journal of Gastroenterology*, **2010**, 105, 814-20; quiz 813, 821	0.7	72
82	Biofeedback treatment for functional anorectal disorders: a comprehensive efficacy review. *Applied Psychophysiology Biofeedback*, **2004**, 29, 153-74	3.4	72
81	Risk factors for urinary, fecal, or dual incontinence in the NurseQHealth Study. *Obstetrics and Gynecology*, **2013**, 122, 539-45	4.9	71

80	The international anorectal physiology working group (IAPWG) recommendations: Standardized testing protocol and the London classification for disorders of anorectal function. *Neurogastroenterology and Motility*, **2020**, 32, e13679	4	70
79	The usual medical care for irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2004**, 20, 1305-15	6.1	67
78	Treatment of fecal incontinence: state of the science summary for the National Institute of Diabetes and Digestive and Kidney Diseases workshop. *American Journal of Gastroenterology*, **2015**, 110, 138-46; quiz 147	0.7	63
77	Mechanisms of constipation in older persons and effects of fiber compared with placebo. *Journal of the American Geriatrics Society*, **1995**, 43, 666-9	5.6	63
76	Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. *American Journal of Gastroenterology*, **2006**, 101, 1057-65	0.7	62
75	Design of Treatment Trials for Functional Gastrointestinal Disorders. *Gastroenterology*, **2016**, 150, 1469-1480.e1	13.3	62
74	Risk factors for fecal incontinence in older women. *American Journal of Gastroenterology*, **2013**, 108, 113-9	0.7	61
73	The impact of fecal and urinary incontinence on quality of life 6 months after childbirth. *American Journal of Obstetrics and Gynecology*, **2007**, 197, 636.e1-6	6.4	60
72	Loperamide Versus Psyllium Fiber for Treatment of Fecal Incontinence: The Fecal Incontinence Prescription (Rx) Management (FIRM) Randomized Clinical Trial. *Diseases of the Colon and Rectum*, **2015**, 58, 983-93	3.1	55
71	Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar. *Journal of Clinical Gastroenterology*, **2009**, 43, 214-20	3	55
70	IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. *American Journal of Gastroenterology*, **2012**, 107, 286-95	0.7	54
69	Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report. *Gastroenterology*, **2009**, 137, 1944-53.e1-3	13.3	53
68	How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. *American Journal of Gastroenterology*, **2018**, 113, 1017-1025	0.7	49
67	Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). *BioPsychoSocial Medicine*, **2007**, 1, 6	2.8	48
66	Habit training as treatment of encopresis secondary to chronic constipation. *Journal of Pediatric Gastroenterology and Nutrition*, **1985**, 4, 397-401	2.8	47
65	Diagnosis and treatment of pelvic floor disorders: what's new and what to do. *Gastroenterology*, **2010**, 138, 1231-5, 1235.e1-4	13.3	46
64	Hypnosis home treatment for irritable bowel syndrome: a pilot study. *International Journal of Clinical and Experimental Hypnosis*, **2006**, 54, 85-99	1.8	40
63	The role of biofeedback in the treatment of gastrointestinal disorders. *Nature Reviews Gastroenterology & Hepatology*, **2008**, 5, 371-82		39

62	Control groups appropriate for behavioral interventions. *Gastroenterology*, **2004**, 126, S159-63	13.3	39
61	Management of the multiple symptoms of irritable bowel syndrome. *The Lancet Gastroenterology and Hepatology*, **2017**, 2, 112-122	18.8	38
60	Survey of geriatricians on the effect of fecal incontinence on nursing home referral. *Journal of the American Geriatrics Society*, **2010**, 58, 1058-62	5.6	36
59	Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. *Neurogastroenterology and Motility*, **2011**, 23, 944-e400	4	35
58	Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic effects. *International Journal of Clinical and Experimental Hypnosis*, **2006**, 54, 7-20	1.8	33
57	Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. *BMC Complementary and Alternative Medicine*, **2009**, 9, 24	4.7	32
56	Is functional dyspepsia just a subset of the irritable bowel syndrome?. *Baillieres Clinical Gastroenterology*, **1998**, 12, 443-61		32
55	Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. *Digestive Diseases and Sciences*, **2004**, 49, 1236-43	4	32
54	Brief telephone-delivered cognitive behavioral therapy targeted to parents of children with functional abdominal pain: a randomized controlled trial. *Pain*, **2017**, 158, 618-628	8	31
53	Episodic nature of symptoms in irritable bowel syndrome. *American Journal of Gastroenterology*, **2014**, 109, 1450-60	0.7	29
52	Rome III survey of irritable bowel syndrome among ethnic Malays. *World Journal of Gastroenterology*, **2012**, 18, 6475-80; discussion p. 6479	5.6	29
51	Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 698-710	18.8	28
50	Validity and Reliability of the Japanese Version of the Rome III Diagnostic Questionnaire for Irritable Bowel Syndrome and Functional Dyspepsia. *Journal of Neurogastroenterology and Motility*, **2015**, 21, 537-44	4.4	28
49	Factor analysis of bowel symptoms in US and Italian populations. *Digestive and Liver Disease*, **2003**, 35, 774-83	3.3	26
48	Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. *Complementary Therapies in Medicine*, **2014**, 22, 17-20	3.5	24
47	Factors that affect consultation and screening for fecal incontinence. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 709-16	6.9	22
46	Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. *American Journal of Medicine*, **1999**, 107, 33S-40S	2.4	21
45	Conservative and behavioural management of constipation. *Neurogastroenterology and Motility*, **2009**, 21 Suppl 2, 55-61	4	19

44	Controlling anal incontinence in women by performing anal exercises with biofeedback or loperamide (CAPABLe) trial: Design and methods. *Contemporary Clinical Trials*, **2015**, 44, 164-174	2.3	17
43	Improving biofeedback for the treatment of fecal incontinence in women: implementation of a standardized multi-site manometric biofeedback protocol. *Neurogastroenterology and Motility*, **2017**, 29, e12906	4	17
42	Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study. *Neurogastroenterology and Motility*, **2019**, 31, e13483	4	17
41	Definition of a responder in clinical trials for functional gastrointestinal disorders: report on a symposium. *Gut*, **1999**, 45 Suppl 2, II78-9	19.2	16
40	Increased Long-term Dietary Fiber Intake Is Associated With a Decreased Risk of Fecal Incontinence in Older Women. *Gastroenterology*, **2018**, 155, 661-667.e1	13.3	15
39	Rome foundation Asian working team report: Real world treatment experience of Asian patients with functional bowel disorders. *Journal of Gastroenterology and Hepatology (Australia)*, **2017**, 32, 1450-1456	4	14
38	Validity and reliability of the Malay-language translation of the Rome III Diagnostic Questionnaire for irritable bowel syndrome. *Journal of Gastroenterology and Hepatology (Australia)*, **2012**, 27, 746-50	4	14
37	Development and validation of new disease-specific measures of somatization and comorbidity in IBS. *Journal of Psychosomatic Research*, **2012**, 73, 351-5	4.1	14
36	Priorities for treatment research from different professional perspectives. *Gastroenterology*, **2004**, 126, S180-5	13.3	14
35	Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. *North Carolina Medical Journal*, **2016**, 77, 211-5	0.6	14
34	Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. *Gastroenterology*, **2017**, 152, 1915-1921.e1	13.3	13
33	Fecal Incontinence Diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 385-391	6.9	13
32	Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. *Neurogastroenterology and Motility*, **2017**, 29, e12919	4	12
31	If We Don't Ask, They Won't Tell: Screening for Urinary and Fecal Incontinence by Primary Care Providers. *Journal of the American Board of Family Medicine*, **2018**, 31, 774-782	1.6	12
30	Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	11
29	Relationship between symptoms and quality of life in fecal incontinence. *Neurogastroenterology and Motility*, **2018**, 30, e13241	4	11
28	Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. *Neurogastroenterology and Motility*, **2016**, 28, 783-92	4	10
27	Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 277-287.e3	6.9	10

26	Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. *Neurogastroenterology and Motility*, **2018**, 30, e13378	4	10
25	Hypnosis for non-cardiac chest pain. *Gut*, **2006**, 55, 1381-4	19.2	9
24	Factors associated with fecal incontinence in a nationally representative sample of diabetic women. *International Urogynecology Journal*, **2015**, 26, 1483-8	2	8
23	Patient preferences for endpoints in fecal incontinence treatment studies. *Neurogastroenterology and Motility*, **2017**, 29, e13032	4	7
22	Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. *Alimentary Pharmacology and Therapeutics*, **2017**, 45, 14-26	6.1	7
21	Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. *Neurogastroenterology and Motility*, **2020**, 32, e13975	4	7
20	Impact of eating restriction on gastrointestinal motility in adolescents with IBS. *Journal of Pediatric Gastroenterology and Nutrition*, **2014**, 58, 491-4	2.8	6
19	Likelihood of nursing home referral for fecally incontinent elderly patients is influenced by physician views on nursing home care and outpatient management of fecal incontinence. *Journal of the American Medical Directors Association*, **2012**, 13, 350-4	5.9	6
18	Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. *United European Gastroenterology Journal*, **2021**,	5.3	6
17	Physical Activity, BMI, and Risk of Fecal Incontinence in the Nurses'Q Health Study. *Clinical and Translational Gastroenterology*, **2018**, 9, 200	4.2	6
16	Biofeedback for fecal incontinence and constipation: The role of medical management and education. *Gastroenterology*, **2001**, 120, A397	13.3	5
15	Obstetric sphincter injury interacts with diarrhea and urgency to increase the risk of fecal incontinence in women with irritable bowel syndrome. *Female Pelvic Medicine and Reconstructive Surgery*, **2013**, 19, 40-5	1.9	4
14	Is fecal incontinence a risk factor for institutionalization in the elderly?. *American Journal of Gastroenterology*, **2011**, 106, 366-7; author reply 367	0.7	4
13	ACG Clinical Guidelines: Management of Benign Anorectal Disorders. *American Journal of Gastroenterology*, **2021**, 116, 1987-2008	0.7	4
12	A genetic polymorphism that is associated with mitochondrial energy metabolism increases risk of fibromyalgia. *Pain*, **2020**, 161, 2860-2871	8	4
11	A multicenter study of anorectal pressures and rectal sensation measured with portable manometry in healthy women and men. *Neurogastroenterology and Motility*, **2021**, 33, e14067	4	3
10	Adopting new enrollment criteria for pharmaceutical trials in constipation: look before leaping. *Therapeutic Advances in Gastroenterology*, **2011**, 4, 165-8	4.7	2
9	Phenotypic profile clustering pragmatically identifies diagnostically and mechanistically informative subgroups of chronic pain patients. *Pain*, **2021**, 162, 1528-1538	8	2

8	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. *Neurogastroenterology and Motility*, **2021**, 33, e14070	4	2
7	Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	1
6	Comparative effectiveness of biofeedback and injectable bulking agents for treatment of fecal incontinence: Design and methods. *Contemporary Clinical Trials*, **2021**, 107, 106464	2.3	1
5	Anorectal physiology in health: A randomized trial to determine the optimum catheter for the balloon expulsion test. *Neurogastroenterology and Motility*, **2019**, 31, e13582	4	
4	Behavioral Treatment of Fecal Incontinence **2014**, 787-806		
3	Is biofeedback therapy an effective treatment for dyssynergic defecation?. *Nature Reviews Gastroenterology & Hepatology*, **2008**, 5, 74-5		
2	Constipation: will the bowel recipe do the trick?. *Obstetrics and Gynecology*, **2007**, 109, 985-9	4.9	
1	Fecal Incontinence **2020**, 427-430		